Bernardo Cortese (Fondazione Ricerca e Innovazione Cardiovascolare, IT) discusses the main findings from the EASTBOURNE Study, that investigated the sirolimus-coated balloon in an all-comer population.
Findings are positive as regards the device’s safety and efficacy profile, with the primary endpoint of target lesion revascularization (TLR) occurring in 6% of the population.
Full interview available here:
Fondazione RIC is inviting you.
It is a real pleasure and honor, to share and invite you at the first co-sponsorized symposium on paclitaxel DCB, during EuroPCR 2022. The Course will have the top-in-class Experts on the DCB technology, and will be held in ROOM 252B, Wednesday 18th, 16.30-17.30. Join us if you are attending this years’ EuroPCR!
Course Programme @ https://bit.ly/3OY2nkw
Webinar rivolto a MMG e Cardiologi, sulle ultime novità in tema di Ipercolesterolemie. Responsabile scientifico Dr Bernardo Cortese, relatori: Dr G Musumeci, Prof A Corsini, D.ssa AM Fiorenza, D.ssa E Iardino, D.ssa A Montorio.
My moderation during the sponsorized Medalliance session @ EuroPCR ’21. Great and didactical session!
Watch this session presented by Antonio Colombo, Bernardo Cortese and Sandeep Basavarajaiah in order to understand the strategy behind using a #DrugCoatedBalloon as a proper solution for CAD and the result and potential of using a Sirolimus DCB in coronary intervention, as well as to get insights into a real-world experience with the #MagicTouch in current clinical practice. #SirolimusCoatedBalloon #EuroPCR PCR